10/2023. Phase 2 clinical trial with birch-mannan

First phase 2 clinical trial with mannan-conjugated polymerized birch (Betula) pollen allergoids published in Allergy.

Birch pollen is one of the major causes of respiratory allergy in central and northern Europe. This study aims to determine the optimal dose in terms of efficacy and safety of the allergoid conjugate with only 5 administrations before the pollen season.

This clinical trial complements the previous study  conducted with polymerized, mannan-conjugated mite allergoids.

Mannan-conjugated polymerized allergoids are a new concept of immunotherapy targeting dendritic cells developed by INMUNOTEK.

More info here.